64 results
POS AM
ABVC
ABVC BioPharma Inc
25 Apr 24
Prospectus update (post-effective amendment)
2:38pm
2534200
Cross-linked oxidized hyaluronic acid for use as a vitreous substitute
European Union (Germany, United Kingdom, France, Switzerland, Spain, Italy
424B4
ABVC
ABVC BioPharma Inc
5 Apr 24
Prospectus supplement with pricing info
2:47pm
substitute
European Union (Germany, United Kingdom, France, Switzerland, Spain, Italy)
NHRI
granted
Cross-linked oxidized hyaluronic acid for use
DEFA14A
ABVC
ABVC BioPharma Inc
25 Mar 24
Additional proxy soliciting materials
4:30pm
-linked oxidized hyaluronic acid for use as a vitreous substitute
European Union (Germany, United Kingdom, France, Switzerland, Spain, Italy)
NHRI
8-K
EX-99.1
ABVC
ABVC BioPharma Inc
14 Mar 24
ABVC BioPharma Reports Annual 2023 Financials and Provides Fiscal Year 2024 First Quarter Business Update
9:04am
into global coverage, we eagerly await the results of patent applications in the European Union, China, Japan, and others.
On December 30, 2022
8-K
EX-4.1
kmd2jr2m12en pokas4
8 Feb 24
ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share
9:30am
8-K
EX-10.1
axol zkvydg
17 Jan 24
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.3
kjmzsmaqvp7293ken
17 Jan 24
Entry into a Material Definitive Agreement
4:30pm
8-K
EX-10.1
aifysaqdjar9h
20 Nov 23
Entry into a Material Definitive Agreement
8:30am
8-K
EX-10.3
vry3iu
20 Nov 23
Entry into a Material Definitive Agreement
8:30am
8-K
EX-10.1
5b5 ah3r8
27 Jul 23
Entry into a Material Definitive Agreement
9:14am
424B4
c49b6mpvsktpc53s
12 Jun 23
Prospectus supplement with pricing info
4:30pm